Vesigen Therapeutics launches with USD 28.5 million Series A investment led by Leaps by Bayer and Morningside Ventures

Investment addresses today’s challenge to efficiently transport next-generation therapeutics such as cell and gene therapy to the target and unlock their full potential as innovative therapies for patients / Vesigen’s ARMMs technology enables translation of new modalities such as RNAs and gene-editing complexes into novel treatments for multiple diseases
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news